Korean J Gastroenterol.  2012 Nov;60(5):335-338. 10.4166/kjg.2012.60.5.335.

Treatment of Hepatocellular Carcinoma with Drug-eluting Beads Chemoembolization and Liver Transplantation

• Yoon HH
• Jung YK
• Chung DH
• Choi SJ
• Kim JH
• Kim KK

• KMID: 1775801
• DOI: http://doi.org/10.4166/kjg.2012.60.5.335

Abstract

No abstract available.

MeSH Terms

Antineoplastic Agents/*administration & dosage
Carcinoma, Hepatocellular/pathology/*therapy
Chemoembolization, Therapeutic
Doxorubicin/*administration & dosage
*Drug-Eluting Stents
Humans
Liver Neoplasms/pathology/*therapy
*Liver Transplantation
Male
Middle Aged
Tomography, X-Ray Computed
Antineoplastic Agents
Doxorubicin

Figure

• 

  Fig. 1 (A) Transverse arterial phase CT scan showed a 15 mm inner nodule (white arrow) in the lesion that was enhanced and a peripheral one that was not enhanced. (B) Transverse equilibrium phase CT scan showed the enhanced inner portion appears as an area of hypoattenuation (white arrow).

• 

  Fig. 2 (A) Hypervascular tumor staining (white arrows) around previous lipiodol uptaken mass in the right hepatic lobe. (B) Completion arteriogram of the right hepatic artery showed near-complete stasis of blood flow (white arrows) through S6 hepatic artery after transarteral chemoembolization with DC bead®.

• 

  Fig. 3 (A) Main tumor showing complete necrosis. DC bead® was seen within and around the tumor (H&E, ×10). (B) DC bead® within the tumor which was in coagulation necrosis (H&E, ×100). (C) DC bead® buried in fibrous tissue around the tumor. Satellite nodule of hepatocellular carcinoma showing focal necrosis. No foreign body reaction was seen (H&E, ×100). (D) Intrahepatic biloma containing DC bead® (H&E, ×40).

Reference

1. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocelluler carcinoma. Hepatology. 2002. 35:519–524.

2. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007. 46:474–481.

3. Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008. 31:269–280.

4. Martin R, Geller D, Espat J, et al. Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology. 2012. 59:255–260.

5. Lammer J, Malagari K, Vogl T, et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010. 33:41–52.

6. Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012. [Epub ahead of print].

7. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010. 21:327–332.

8. Naumann M, Bonsall R, Gupta R. Chemoembolization with drug-eluting beads complicated by intrahepatic biloma. Semin Intervent Radiol. 2011. 28:212–217.

9. Park WK, Chang JC, Lee HZ, Kim HJ, Choi JH, Gu MJ. A case of resection of biloma with hepatocellular carcinoma after embolization. Korean J Hepatol. 2002. 8:331–335.

10. Kobayashi S, Nakanuma Y, Terada T, Matsui O. Postmortem survey of bile duct necrosis and biloma in hepatocellular carcinoma after transcatheter arterial chemoembolization therapy: relevance to microvascular damages of peribiliary capillary plexus. Am J Gastroenterol. 1993. 88:1410–1415.